PD-L1 Inhibitor TQ-B2450 and Anlotinib Combo Is Promising in Second-Line NSCLC

Targeted Therapies in OncologyFebruary 2, 2022
Volume 11
Issue 3
Pages: 32

Positive phase 1 results of TQ-B2450 combined with anlotinib have lead to a phase 3 study of the combination versus pembrolizumab in patient with PD-L1 positive advanced non–small cell lung cancer.

The novel anti-PD-L1 ntibody TQ-B2450 in combination with anlotinib, a multitargeting tyrosine kinase inhibitor, led to an improvement in efficacy over immunotherapy alone in previously treated patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, randomized phase 1 trial (NCT03910127) presented during the European Society for Medical Oncology Immuno-Oncology Congress 2021. “PFS [progression-free survival] and ORR [objec- tive response rate] with TQ-B2450 combined with anlotinib were significantly improved compared with the control group [in patients with advanced NSCLC],” said Baohui Han, MD, PhD, professor of respiratory medicine at Shanghai Chest Hospital of Shanghai Jiao Tong University in China. “TQ-B2450 combined with anlotinib may be a promising treatment for advanced NSCLC.”

Enrolled patients had stage IIIB-IV NSCLC, an ECOG performance status of 0 or 1, and received at least 1 line of chemo- therapy but had failed or were intolerant to treatment. Additionally, patients were EGFR and ALK wild type and were not restricted by PD-L1 tumor proportion score (TPS) levels.

A total of 101 patients were randomized equally between 3 treatment arms: TQ-B2450 at 1200 mg intravenously (IV) on day 1 of each 21-day cycle plus anlotinib at 12 mg daily on days 1 to 14 of the cycle, TQ-B2450 at 1200 mg IV and anlotinib at 10 mg daily, or TQ-B2450 at 1200 mg IV plus placebo. Treatment continued until progressive disease or intolerance to treatment. However, the 2 doublet arms were later combined (n=68) and compared with the monotherapy arm (n = 33), as the average daily exposed dose of anlotinib was 10.2 mg.

The primary end point was PFS, and sec- ondary end points included safety, ORR, disease control rate (DCR), duration of response (DOR), and overall survival.

In the merged combination arm, the median age was 61.5 years (range, 30-73), 69.12% were men, 95.59% had an ECOG performance status of 1, and 60.29% were former smokers. The most common pathology was adenocarcinoma in 63.24% of patients followed by squamous cell carcinoma in 20.59%, but was unknown in 16.18%. Most patients had stage IV disease (80.88%), no brain metastases (86.67%), and positive PD-L1 expression (88.37%).

In the monotherapy arm, the median age was 60 years (range, 47-77), 81.82% were men, 93.94% had an ECOG performance status of 1, and 66.67% were former smokers. A total of 63.64% of patients had adenocarcinoma vs squamous cell carcinoma pathology in 27.27%, and 82.76% had stage IV disease. Brain metas- tases were reported in 27.27%, and 79.27% had positive PD-L1 TPS of 1% or higher.

At a median follow-up of 11.1 months, the median PFS with the combination of TQ-B2450 and anlotinib was 6.9 months (95% CI, 5.3-12.4) vs 2.7 months (95% CI, 1.4-4.7) with TQ-B2450 alone (HR, 0.43; 95% CI, 0.25-0.73; P = .0014). Across prespecified subgroups, PFS favored the doublet arm, except in currently smoking patients (HR, 1.09; 95% CI, 0.20-6.05).

In the combination arm, the ORR was 30.9% (95% CI, 20.2%-43.3%), consisting of all partial responses. Stable disease (SD) was achieved by 42.6% of patients, resulting in a DCR of 73.5% (95% CI, 61.4%-83.5%). In the monotherapy arm, the ORR was 3.0% (95% CI, 0.1%-15.8%), and 51.5% achieved SD, for a DCR of 54.6% (95% CI, 36.4%-71.9%). The difference between the 2 arms in response was 27.9 percentage points (P = .0043) and 18.9 percentage points for dis- ease control (P = .1620). The median DOR in the combination arm was 16.6 months and was not evaluable in the monotherapy arm (P = .8195).

Adverse events (AEs) were reported in all patients in the combination arm and in all but 2 in the monotherapy arm. In the doublet arm, 92.65% of events were considered TQ-B2450 related and 94.12% were considered related to anlotinib. Grade 3 or higher treatment-emer- gent AEs were reported in 67.65% and serious AEs in 41.18%. Anlotinib dosing was disrupted in 33.82% of patients, adjusted in 22.06%, and discontinued in 20.59%. In the monotherapy arm, 84.85% of patients had treatment-related AEs, grade 3 or higher events were reported in 21.21%, and serious AEs in 15.15%.

The most common treatment-related AEs of any grade in the combination arm were hypertension (48.53%), hypertriglyceridemia (42.65%), increased aspartate aminotrans- ferase levels (35.29%), increased thyroid- stimulating hormone levels (35.29%), and increased alanine aminotransferase (ALT) levels (32.35%). Common grade 3/4 AEs with the doublet included hypertension (19.12%) and hypertriglyceridemia (8.82%).

With single-agent TQ-B2450, the most com- mon treatment-related events of any grade were anemia (24.24%), hyperglycemia (24.24%), increased ALT levels (21.21%), and loss of appe- tite (18.18%). Only 1 grade 3/4 was reported in the monotherapy arm of hypertension.

Han noted that a randomized, controlled phase 3 trial (NCT04964479) is ongoing, exploring the combination of TQ-B2450 and anlotinib vs pembrolizumab (Keytruda) in the treatment of patients with advanced NSCLC and positive PD-L1 expression.


Han B, Li K, Wang Q, Cheng Y, Yang L, Li Y. The efficacy and safe- ty of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): a multicenter, randomized, dou- ble-blind clinical trial. Presented at: ESMO Immuno-Oncology Con- gress 2021; December 8-11, 2021; virtual. Abstract LBA4.

Related Videos
Expert on lung cancer
Expert on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on NSCLC
Experts on NSCLC